• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression first line treatment for depression and anxiety

For a lot of people suffering from depression, traditional therapy and medication are ineffective. A customized treatment may be the answer.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into personalised micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each person, using Shapley values, in order to understand their feature predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 However, only about half of those suffering from the condition receive treatment1. To improve the outcomes, clinicians need to be able to identify and treat patients who have the highest likelihood of responding to specific treatments.

The ability to tailor depression treatments is one way to do this. By using sensors for mobile phones and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from the treatments they receive. Two grants were awarded that total more than $10 million, they will employ these techniques to determine the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

The majority of research into predictors of depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographic variables such as age, gender and educational level, clinical characteristics like symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these aspects can be predicted from information in medical records, few studies have utilized longitudinal data to study the factors that influence mood in people. A few studies also take into consideration the fact that moods can differ significantly between individuals. Therefore, it is crucial to create methods that allow the recognition of the individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behavior and emotions that are unique to each individual.

The team also created a machine-learning algorithm that can model dynamic predictors for the mood of each person's depression. The algorithm blends the individual characteristics to create a unique "digital genotype" for each participant.

This digital phenotype was linked to CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was low however (Pearson r = 0,08; BH adjusted P-value 3.55 x 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 yet it is often underdiagnosed and undertreated2. In addition, a lack of effective treatments and stigmatization associated with depressive disorders stop many individuals from seeking help.

To facilitate personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the methods used to predict symptoms rely on clinical interview, which has poor reliability and only detects a small number of symptoms associated with depression.2

Using machine learning to combine continuous digital behavioral phenotypes captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) together with other predictors of symptom severity has the potential to improve diagnostic accuracy and increase tms treatment for depression efficacy for depression treatment residential. Digital phenotypes can be used to capture a large number of unique behaviors and activities that are difficult to record through interviews and permit continuous, high-resolution measurements.

The study included University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical care depending on their depression severity. Participants with a CAT-DI score of 35 65 were assigned online support via an instructor and those with scores of 75 patients were referred to in-person psychotherapy.

Participants were asked a series questions at the beginning of the study concerning their psychosocial and demographic characteristics as well as their socioeconomic status. These included age, sex education, work, and financial status; if they were divorced, partnered or single; the frequency of suicidal ideas, intent or attempts; and the frequency at which they drank alcohol. Participants also rated their degree of depression treatment free (Highly recommended Online site) severity on a scale of 0-100 using the CAT-DI. The CAT-DI test was performed every two weeks for those who received online support, and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focused on individualized depression treatment. Many studies are focused on identifying predictors, which will help doctors determine the most effective drugs for each person. Pharmacogenetics in particular identifies genetic variations that determine the way that our bodies process drugs. This lets doctors select the medication that are likely to be the most effective for each patient, while minimizing the time and effort needed for trial-and-error treatments and avoiding any side consequences.

Another promising method is to construct models of prediction using a variety of data sources, such as data from clinical studies and neural imaging data. These models can be used to determine the most effective combination of variables that is predictors of a specific outcome, like whether or not a particular medication to treat anxiety and depression is likely to improve the mood and symptoms. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness of their treatment.

A new era of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables to improve predictive accuracy. These models have shown to be useful in predicting treatment outcomes such as the response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the standard for the future of clinical practice.

In addition to ML-based prediction models The study of the mechanisms behind depression continues. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This suggests that individualized depression treatment will be built around targeted treatments that target these circuits in order to restore normal functioning.

Internet-based interventions are an effective method to achieve this. They can provide a more tailored and individualized experience for patients. A study showed that an internet-based program improved symptoms and led to a better quality of life for MDD patients. Furthermore, a randomized controlled study of a personalised treatment for depression demonstrated sustained improvement and reduced adverse effects in a large percentage of participants.

Predictors of adverse effects

In the treatment of depression, the biggest challenge is predicting and identifying which antidepressant medication will have no or minimal side negative effects. Many patients take a trial-and-error approach, using a variety of medications prescribed until they find one that is effective and tolerable. Pharmacogenetics offers a fascinating new way natural ways to treat depression and anxiety take an efficient and targeted approach to selecting antidepressant treatments.

A variety of predictors are available to determine the best antidepressant to prescribe, including genetic variants, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. To identify the most reliable and accurate predictors for a specific treatment, controlled trials that are randomized with larger numbers of participants will be required. This is because it could be more difficult to identify moderators or interactions in trials that only include one episode per person instead of multiple episodes over a long period of time.

Furthermore the prediction of a patient's response to a particular medication is likely to require information on comorbidities and symptom profiles, and the patient's previous experiences with the effectiveness and tolerability of the medication. There are currently only a few easily assessable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

Many issues remain to be resolved when it comes to the use of pharmacogenetics in the treatment of depression. It is crucial to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, as well as an understanding of an accurate indicator of the response to treatment. Ethics like privacy, and the ethical use of genetic information are also important to consider. In the long-term the use of pharmacogenetics could be a way to lessen the stigma associated with mental health treatment and to improve the treatment outcomes for patients with depression. Like any other psychiatric treatment, it is important to carefully consider and implement the plan. At present, the most effective course of action is to offer patients various effective depression medications and encourage them to talk with their physicians about their experiences and concerns.